Asian Stock Selections Estimated Below Market Value April 2026

As Asian markets navigate the complexities of geopolitical developments and economic data, investors are increasingly focused on identifying opportunities that may be undervalued by the broader market. In such an environment, a good stock is often characterized by strong fundamentals and resilience to external pressures, making it well-positioned to capitalize on potential market shifts.

Click here to see the full list of 198 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Overview: STI Co., Ltd. operates in the semiconductor equipment industry in Korea with a market cap of approximately ₩524.67 billion.

Operations: The company’s revenue primarily comes from its Semiconductor Equipment and Display Equipment segment, totaling approximately ₩328.06 billion.

Estimated Discount To Fair Value: 40.9%

STI is trading at ₩36,400, significantly below its estimated future cash flow value of ₩61,579.07, indicating it might be undervalued. The company is expected to see robust revenue growth of 35.6% per year and earnings growth of 60.8%, both surpassing the Korean market averages. Despite recent volatility and a decline in profit margins from 8.1% to 4.7%, STI’s long-term growth prospects remain strong based on cash flow projections.

Overview: Xunfei Healthcare Technology Co., Ltd. offers healthcare AI solutions in the People’s Republic of China and has a market capitalization of approximately HK$8.64 billion.

Operations: Xunfei Healthcare Technology Co., Ltd. generates its revenue through healthcare AI solutions in China.

Estimated Discount To Fair Value: 13%

Xunfei Healthcare Technology trades at HK$71.45, slightly below its estimated future cash flow value of HK$82.09, reflecting potential undervaluation. The company anticipates revenue growth of 23.6% annually, outpacing the Hong Kong market rate of 8.6%. Despite a net loss reduction from CNY 132.6 million to CNY 64.79 million in 2025 and expected profitability within three years, its low forecasted return on equity remains a concern for investors evaluating long-term prospects based on cash flows.

Overview: Zhejiang Meili High Technology Co., Ltd. focuses on the research, development, production, and sale of high-end spring products both in China and internationally, with a market cap of CN¥5.80 billion.

Operations: Zhejiang Meili High Technology Co., Ltd. derives its revenue from the research, development, production, and sale of high-end spring products for domestic and international markets.

Estimated Discount To Fair Value: 17.8%

Zhejiang Meili High Technology is trading at CNY 27.49, under its future cash flow value of CNY 33.46, suggesting potential undervaluation. The company reported a revenue increase to CNY 2 billion in 2025 and net income growth to CNY 145.9 million, reflecting strong financial performance. With forecasted earnings growth of over 28% annually and high return on equity expectations, it presents an attractive investment opportunity despite an unstable dividend history.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include KOSDAQ:A039440 SEHK:2506 and SZSE:300611.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]